D'Auria G - Search Results

1

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.

Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Fabbri A, et al. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. eCollection 2023. Front Oncol. 2023. PMID: 37441419 Free PMC article.

2

EGFR inhibitors: clinical results.

De Marinis F, Nelli F, D'Auria G. De Marinis F, et al. Suppl Tumori. 2002 Nov-Dec;1(6):S5-6. doi: 10.1177/03008916020016s102. Suppl Tumori. 2002. PMID: 12658893 Review. No abstract available.

3

Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.

Nelli F, Naso G, De Pasquale Ceratti A, Saltarelli R, Dauria G, Lugini A, Ferraldeschi R, Picone V, Moscetti L, Cortesi E. Nelli F, et al. J Chemother. 2004 Aug;16(4):392-9. doi: 10.1179/joc.2004.16.4.392. J Chemother. 2004. PMID: 15332716 Clinical Trial.

4

Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology.

Moscetti L, Nelli F, Felici A, Rinaldi M, De Santis S, D'Auria G, Mansueto G, Tonini G, Sperduti I, Pollera FC. Moscetti L, et al. Cancer. 2007 Jan 15;109(2):274-81. doi: 10.1002/cncr.22399. Cancer. 2007. PMID: 17154161 Free article.

5

A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.

Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I, Zeuli M, Cortesi E, D'Auria G, Pollera CF. Gamucci T, et al. Clin Colorectal Cancer. 2008 Jul;7(4):273-9. doi: 10.3816/CCC.2008.n.035. Clin Colorectal Cancer. 2008. PMID: 18650196 Clinical Trial.

6

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.

Nelli F, Moscetti L, Natoli G, Massari A, D'Auria G, Chilelli M, Fabbri MA, Frittelli P, Ruggeri EM. Nelli F, et al. Int J Clin Oncol. 2013 Apr;18(2):343-9. doi: 10.1007/s10147-012-0384-x. Epub 2012 Feb 17. Int J Clin Oncol. 2013. PMID: 22350024

7

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Fabi A, et al. BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482. BMC Cancer. 2012. PMID: 23083011 Free PMC article.

8

Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis.

Nelli F, Natoli G, Moscetti L, Massari A, D'Auria G, Fabbri MA, Frittelli P, Ruggeri EM. Nelli F, et al. J Chemother. 2013 Apr;25(2):112-8. doi: 10.1179/1973947812Y.0000000059. J Chemother. 2013. PMID: 23684359

9

Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?

Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM. Moscetti L, et al. Tumori. 2015 Sep-Oct;101(5):469-73. doi: 10.5301/tj.5000376. Epub 2015 Jun 13. Tumori. 2015. PMID: 26108239

10

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, Barba M, Ruggeri EM. Moscetti L, et al. Oncotarget. 2017 Apr 20;8(33):54528-54536. doi: 10.18632/oncotarget.17262. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903361 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters